These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8996531)

  • 21. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of Liposomal Formulations on the Release and Brain Delivery of Methotrexate: An In Vivo Microdialysis Study.
    Hu Y; Rip J; Gaillard PJ; de Lange ECM; Hammarlund-Udenaes M
    J Pharm Sci; 2017 Sep; 106(9):2606-2613. PubMed ID: 28322936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intra-arterial infusion of cisplatin and caffeine for a recurrent malignant fibrous histiocytoma].
    Tsuchiya H; Tomita K; Yasutake H; Morishita H; Morikawa S; Ono M; Tsuchida T; Takagi Y
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):681-4. PubMed ID: 2157370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
    Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH
    Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carboxypeptidase G2 rescue after high-dose methotrexate.
    DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
    J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
    Glantz MJ; Cole BF; Recht L; Akerley W; Mills P; Saris S; Hochberg F; Calabresi P; Egorin MJ
    J Clin Oncol; 1998 Apr; 16(4):1561-7. PubMed ID: 9552066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
    Bain E; Birhiray RE; Reeves DJ
    Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intratumoral methotrexate kinetics in a patient with intracranial anaplastic ependymoma.
    Geis T; Peters O; Friedrich M; Dränert E; Wolff JE
    Pediatr Blood Cancer; 2004 Jul; 43(1):78-80. PubMed ID: 15170895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant fibrous histiocytoma of the scalp. Multidisciplinary treatment.
    Camacho FM; Moreno JC; Murga M; Proaño J; Cantillana J; Naranjo M; Martínez-Sahuquillo A; Macher G; Romero F
    J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):175-82. PubMed ID: 10642053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue.
    Dukic SF; Kaltenbach ML; Heurtaux T; Hoizey G; Lallemand A; Vistelle R
    J Neurooncol; 2004; 67(1-2):131-8. PubMed ID: 15072460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
    Chan BS; Dawson AH; Buckley NA
    Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy.
    Inose R; Takahashi K; Nanno S; Hino M; Nagayama K
    J Chemother; 2019 Feb; 31(1):30-34. PubMed ID: 30773130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
    Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
    Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma.
    Thomson AH; Daly M; Knepil J; Harden P; Symonds P
    Cancer Chemother Pharmacol; 1996; 38(6):566-70. PubMed ID: 8823500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
    Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
    J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Individual dose adjustment of high-dose methotrexate in clinical practice].
    Bagarry-Liégey D; Nicoara A; Duffaud F; Guillet P; Pignon T; Catalin J; Durand A; Favre R
    Rev Med Interne; 1996; 17(8):689-98. PubMed ID: 8881200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of prehydration on the clearance and toxicity of high-dose methotrexate for pediatric patients.
    Karremann M; Sauerbier J; Meier C; Vetter C; Schneider H; Buchholz B; Mildenberger S; Dürken M
    Leuk Lymphoma; 2014 Dec; 55(12):2874-8. PubMed ID: 24576168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of methotrexate in solid tumors.
    Jain RK; Wei J; Gullino PM
    J Pharmacokinet Biopharm; 1979 Apr; 7(2):181-94. PubMed ID: 20218013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
    Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
    Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.